Nucleix Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nucleix.com
Bladder EpiCheck European Haematuria Study
- Conditions
- Urothelial Carcinoma of the Urinary BladderHematuriaUrothelial Carcinoma of the Renal Pelvis and UreterCystoscopyUrothelial Carcinoma Bladder
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06818136
- Locations
- 🇬🇧
NHS Lothian, Edinburgh, United Kingdom
Lung EpiCheck Biomarkers Development Study
- Conditions
- Lung Cancer
- Interventions
- Other: Blood collection
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT06245876
- Locations
- 🇺🇸
Ochsner LSU Health Shreveport - Regional Urology, Shreveport, Louisiana, United States
🇺🇸Comprehensive Urology, Southfield, Michigan, United States
🇺🇸Life Spring Clinical Research, Miami, Florida, United States
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
- Conditions
- Non-Muscle Invasive Bladder Urothelial CarcinomaNon Muscle Invasive Bladder Cancer
- Interventions
- Diagnostic Test: Bladder EpiCheck
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06020807
- Locations
- 🇺🇸
Urology San Antonio, San Antonio, Texas, United States
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
- Conditions
- Lung Cancer
- Interventions
- Procedure: Blood collection
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 5000
- Registration Number
- NCT04968548
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Durham VA Health Care System, Durham, North Carolina, United States
🇺🇸Scripps Memorial Hospital, Encinitas, California, United States
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
- Conditions
- CancerHematologic NeoplasmsSolid Tumor
- Interventions
- Procedure: Blood collection
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 800
- Registration Number
- NCT04264767
- Locations
- 🇮🇱
Sourasky Medical Center, Tel Aviv, Israel
🇺🇸Los Angeles Hematology Oncology Medical Group - Wilson Terrace, Glendale, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices, Los Angeles, California, United States
Characterization of Methylation Patterns in Hepatocellular Carcinoma
- Conditions
- CirrhosisHepatocellular CarcinomaHepatocellular Cancer
- Interventions
- Procedure: Blood collection
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04264754
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Ha'emek Medical Center, Afula, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
- Conditions
- Bladder Cancer
- Interventions
- Device: Bladder EpiCheck Urine TestProcedure: Cystoscopy and pathology
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 680
- Registration Number
- NCT02700464
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸The Urology Center of Colorado, Denver, Colorado, United States
🇺🇸Urological Surgeons of Long Island, Garden City, New York, United States
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
- Conditions
- Bladder Cancer
- Interventions
- Other: Bladder EpiCheck
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 1050
- Registration Number
- NCT02647112
- Locations
- 🇩🇪
Tubingen University Medical Center, Tubingen, Germany
🇳🇱ZGT Medical Center, Hengelo, Netherlands
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
Characterization of Methylation Patterns in Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 683
- Registration Number
- NCT02373917
- Locations
- 🇮🇱
Sha'are Tzedaek Medical Center, Jerusalem, Israel